Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR in Prader-Willi Syndrome
NCT00175305Phase 3Terminated
- Sponsor
- University of British Columbia
- Start
- Aug 2004
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of octreotide in Prader-Willi syndrome (PWS), obesity, sponsored by University of British Columbia. Started Aug 2004; status: terminated.
02
Drugs
octreotide
03
Conditions
Prader-Willi syndrome (PWS)obesity
Beyond the preview
Go deeper on NCT00175305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00175305.